Tatva Chintan Pharma Chem DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.75×	0.74×	0.75×	0.70×	1.02×
	0.98×	1.01×	1.16×	1.02×	0.88×
	13.3%	11.1%	1.7%	10.8%	12.0%
	0.55×	0.55×	0.46×	0.50×	0.60×
	1.37×	1.28×	1.13×	1.11×	1.47×
	7.3%	5.9%	0.8%	4.3%	9.5%
	5.5%	5.5%	0.8%	4.9%	9.2%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

TATVA₹1,565.90

Tatva Chintan Pharma Chem Limited

· Chemicals

₹ CrorePeersVISHNU JUBLCPL KIRIINDUS FOSECOIND CHEMPLASTS DDEVPLSTIK GUJALKALI YASHOMcap ₹3,663 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	1.02	0.70	0.75	0.74	0.75
Interest Burden (Pretax/EBIT) ×	0.88	1.02	1.16	1.01	0.98
EBIT Margin %	12.05	10.82	1.71	11.13	13.30
Asset Turnover ×	0.60	0.50	0.46	0.55	0.55
Financial Leverage (Assets/Equity) ×	1.47	1.11	1.13	1.28	1.37
ROE (5-step product, year-end total equity) %	9.47	4.28	0.78	5.87	7.31
ROE (owners' profit / average owners' equity) %	9.21	4.85	0.77	5.53	5.53

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.